- SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the
treatment of moderate to severe plaque
psoriasis.1
- In clinical studies, SKYRIZI® significantly improved levels
of skin clearance after just 16 weeks and maintained clearance at
one year (52 weeks).1
- New Brunswick lists
SKYRIZI® on its provincial formulary effective March 19, 2020.
- Yukon lists SKYRIZI® on its
formulary effective April 1,
2020.
- British Columbia lists
SKYRIZI® on its provincial formulary
effective May 05, 2020.
- Newfoundland and
Labrador lists
SKYRIZI® on its provincial formulary
effective September 16,
2020.
MONTREAL, Oct. 1, 2020 /CNW/ - AbbVie (NYSE: ABBV), a
global, research and development-based biopharmaceutical company,
announced today that SKYRIZI® (risankizumab) is now listed as a
special authorization drug or exception drug status on the
formularies of New Brunswick,
Yukon, British Columbia, and Newfoundland and Labrador for the treatment of moderate to
severe plaque psoriasis.
SKYRIZI® is part of a collaboration between Boehringer Ingelheim
and AbbVie, with AbbVie leading development and commercialization
globally, and is the only IL-23 inhibitor to arrive at a positive
conclusion with the pCPA.
"I have been fortunate to be involved in the clinical trials.
SKYRIZI® has improved the quality of life of my patients with
psoriasis by offering them clear skin," states Dr. Irina Turchin, MD, FRCPC, Fredericton, NB. "It is great to see
that this treatment is now available to more patients in
New Brunswick."
Psoriasis is a chronic condition affecting 125 million people
worldwide, including 1 million Canadians, and many patients despite
treatment still do not reach their goals or lose treatment response
over time.2-4 The most common form is plaque
psoriasis, which affects approximately 90% of patients.
5
"I am excited to be able to offer SKYRIZI® to patients with
moderate to severe psoriasis in British
Columbia as it is now listed on the provincial Pharmacare
formulary. Having experience with the medication in clinical
trials, I have personally seen how it provides durable and complete
skin clearance for many patients. Patients are particularly happy
with the dosing schedule," explains Dr Chih-ho Hong, MD, FRCPC,
Dermatologist.
Psoriasis has a genetic basis and about one-third of people with
psoriasis have at least one family member with the disease.
5 Of note, the prevalence of psoriasis is 5-
to 10-fold higher in Newfoundland
and Labrador than in the rest of
Canada.
6
"PsoriasisNL is pleased to learn of this listing of another
treatment for psoriasis for the patients of our province. We would
like to thank the Government of Newfoundland and Labrador for their continued support of
advanced therapeutics for the patients of this province who suffer
from severe psoriasis. As the province with the highest prevalence
of this disease, the availability of these treatments have greatly
increased the quality of life for those who suffer from psoriasis",
explains Deva Murthy, President, PsoriasisNL.
Information regarding specific reimbursement criteria may be
found by consulting the links below:
- New Brunswick Drug Plans Formulary
- Yukon Health Drug Formulary
- BC PharmaCare Formulary
- Newfoundland and Labrador
Prescription Drug Program Bulletin 139.
About SKYRIZI®
SKYRIZI® is a novel, humanized immunoglobulin monoclonal antibody
designed to selectively inhibit IL-23, a naturally occurring
cytokine involved in inflammatory and immune
responses.1 On April 17,
2019, SKYRIZI™ received a NOC from Health Canada for the
treatment of moderate to severe plaque psoriasis in patients who
are candidates for systemic therapy or phototherapy, based on
results from clinical studies showing significant improvement in
levels of skin clearance after just 16 weeks and at 52 weeks with
every 3-month dosing in more than 2000 adult patients.1
Four pivotal Phase 3 studies, ultIMMa-1, ultIMMa-2,
IMMvent and IMMhance evaluated more than 2,000 patients with
moderate to severe plaque psoriasis.4 Canadians living
with moderate to severe plaque psoriasis were well represented in
all four of the pivotal clinical trials leading to Health Canada's
approval, showing the Canadian leadership in this clinical
development program.
About AbbVie in Dermatology
For more than a decade,
AbbVie has worked to uncover new solutions and improve care for
people with serious skin diseases. With a broad clinical trial
program, we continue to actively research and adapt to the evolving
needs of the dermatology community and advance our pipeline to help
people achieve their treatment goals and live beyond their skin
disease.
About AbbVie Care
The AbbVie Care program is designed
to provide a wide range of customized services including
reimbursement and financial support, pharmacy services, lab work
reminders and coordination, personalized education and ongoing
disease management support throughout the treatment journey.
For more information, consult abbviecare.ca
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines that solve serious health issues today
and address the medical challenges of tomorrow. We strive to have a
remarkable impact on people's lives across several key therapeutic
areas: immunology, oncology, neuroscience, eye care, virology,
women's health and gastroenterology, in addition to products and
services across its Allergan Aesthetics portfolio. For more
information about AbbVie, please visit us
at www.abbvie.ca and www.abbvie.com. Follow
@abbvieCanada and @abbvie on Twitter or view careers on
our Facebook or LinkedIn page.
References:
|
1.
|
SKYRIZI® (risankizumab) [Canadian
Product Monograph]. AbbVie Corporation, April 17,
2019.
|
2.
|
International
Federation of Psoriasis Associations. Accessed March 22, 2019.
Available
at: https://ifpa-pso.com/wp-content/uploads/2017/01/Brochure-Psoriasis-is-a-serious-disease-deserving-global-attention.pdf.
|
3.
|
Mroweitz, U., et al.
Definition of treatment goals for moderate to severe psoriasis: a
European consensus. Arch Dermatol Res. 2011 Jan; 303(1):
1–10.
|
4.
|
Levin, et al.
Biologic fatigue in psoriasis. J Dermatolog Treat. 2014
Feb;25(1):78-82. doi: 10.3109/09546634.2013.826341.
|
5.
|
Canadian Dermatology
Association – Psoriasis. Accessed on September 30, 2020.
|
6.
|
Nall, L., Gulliver,
W., Charmley, P. and Farber, E.M. (1999) Search for the psoriasis
susceptibility gene: The Newfoundland Study. Cutis, 64,
323–329.)
|
SOURCE AbbVie Canada